QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=9A6DB3B64EC4691E87DB5822539F917C;jsessionid=021395EE77A032A88963306DAA958A91;jsessionid=47F0DA14B46A36F32B905FA7DBA6EF20;jsessionid=432163A43F53A9B66D76B91F7E4B2A76;jsessionid=D36B59BC6EBBC633210F45A1D46D9DFC;jsessionid=2D635DEAF6B18F9C39F3E092A2D3E799;jsessionid=B5F74D04217DF028C7CFD657851F5411;jsessionid=102BEE59F2583FFD1F2AE2D3320BD509;jsessionid=A11CB0BA5AFA72094A621B2D05DBE793 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=9A6DB3B64EC4691E87DB5822539F917C;jsessionid=021395EE77A032A88963306DAA958A91;jsessionid=47F0DA14B46A36F32B905FA7DBA6EF20;jsessionid=432163A43F53A9B66D76B91F7E4B2A76;jsessionid=D36B59BC6EBBC633210F45A1D46D9DFC;jsessionid=2D635DEAF6B18F9C39F3E092A2D3E799;jsessionid=B5F74D04217DF028C7CFD657851F5411;jsessionid=102BEE59F2583FFD1F2AE2D3320BD509;jsessionid=A11CB0BA5AFA72094A621B2D05DBE793